The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: dsDNA virus peptides. Buy the report here.

Smarter leaders trust GlobalData

Data Insights Innovation in Pharmaceuticals: dsDNA virus peptides

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Johnson & Johnson

Merck & Co Inc

AstraZeneca Plc

GSK plc

BioNTech SE

View all

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

dsDNA virus peptides are a key innovation area in pharmaceutical

Double-stranded DNA (dsDNA) viruses package their genomic DNA into a procapsid using an ATP-powered nanomotor. According to some studies, the peptide, which is a short chain of amino acids, acts at the early stages of infection upon or immediately after virus entry and has antiviral activity through selective inhibition of viral gene expression, while only transiently altering cellular genes, which are activated in response to viral infection. The peptide, therefore, offers a promising approach to developing a broad-spectrum antiviral drug against double-stranded DNA viruses.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 140+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of dsDNA virus peptides.

Key players in dsDNA virus peptides – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local.’

Patent volumes related to dsDNA virus peptides

GSK is the leading patent filer in dsDNA virus peptides. GSK is a healthcare company which focuses on developing, manufacturing and commercialising pharmaceuticals, vaccines, and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterials, dermatology and rare diseases. GSK’s drug Benlysta is indicated as an add-on therapy in patients aged five years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (for example, positive anti-dsDNA and low complement) despite standard therapy. Johnson & Johnson and Merck are the other key patent filers in dsDNA virus peptides.

In terms of application diversity, IMV is the top company, followed by Assistance Publique - Hopitaux de Paris and Obetech By means of geographic reach, BioNTech holds the top position. Bharat Biotech and AstraZeneca stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.